Major depressive disorder (MDD) remains one of the leading causes of disability worldwide and a major challenge for mental health care. Despite substantial advances in its recognition and treatment, depression continues to confront clinicians and researchers with a fundamental problem: patients sharing the same diagnosis may differ markedly in symptom presentation, neurobiology, cognitive and physical health, environmental exposures, illness trajectories, and response to treatment. This heterogeneity challenges approaches based predominantly on diagnostic categories and overall symptom severity and calls for a broader understanding of what depression is, how it should be characterized, and what constitutes meaningful recovery. The contributions included in this issue of the Spanish Journal of Psychiatry and Mental Health approach these questions from remarkably diverse perspectives, ranging from psychopathology and clinical phenotyping to molecular mechanisms, brain connectivity, cognition, physical health, environmental exposures, and models of care. Collectively, they illustrate why progress in MDD may increasingly depend on our ability to look beyond symptoms while remaining firmly grounded in careful clinical characterization.
The heterogeneity of depression is directly addressed by Flores-Cohaila et al.,1 who challenge its conventional characterization as a largely unidimensional construct defined by overall symptom severity. Using nationally representative data from more than 318,000 individuals in Peru, the authors applied a Research Domain Criteria (RDoC)-informed structure to the PHQ-9 and identified seven distinct depressive phenotypes among individuals with clinically significant symptoms. Particularly noteworthy was an internalizing negative valence phenotype characterized by prominent guilt, worthlessness, and suicidal ideation despite only moderate overall depression severity. This finding illustrates how reliance on total severity symptoms scores may obscure clinically meaningful differences between patients and, importantly, potentially overlook individuals at substantial suicide risk. Although longitudinal and therapeutic validation is still required, this study provides a framework for moving from severity-based classification towards more phenotype-informed approaches to depression, while extending precision psychiatry research to an underrepresented Latin American population.
Yet the pursuit of precision should not lead us to overlook the foundations of clinical psychiatry. In their reflection on the legacy of Julio Vallejo, Soria and Menchón2 revisit his enduring assertion that “clinical symptoms are sovereign” and his insistence on rigorous descriptive psychopathology. His particular interest in melancholic depression reflected the conviction that clinically meaningful depressive presentations may differ in their underlying biology and therapeutic needs. This perspective appears remarkably contemporary. Moving beyond symptom scores does not mean moving beyond psychopathology; rather, careful clinical characterization remains essential for identifying meaningful subgroups and interpreting increasingly sophisticated biological information. Modern attempts to deconstruct MDD through dimensional and biological approaches may therefore be viewed not as a departure from classical psychopathology, but as an opportunity to refine and extend it.
This dialogue between clinical phenotyping and biology is illustrated by Ferrer et al.,3 who focus on cognition, a frequently impaired and clinically relevant dimension of MDD. By examining genetic and epigenetic variation in NR3C1, which encodes the glucocorticoid receptor and plays a key role in hypothalamic–pituitary–adrenal axis regulation, the authors identify associations between specific polymorphisms and methylation patterns and cognitive performance, particularly executive functioning. Although these exploratory findings require replication, they illustrate the potential value of integrating genetic, epigenetic, and neurocognitive information to characterize biologically meaningful dimensions of depression. Rather than searching for biomarkers of MDD as a single heterogeneous entity, identifying mechanisms associated with specific clinical and functional phenotypes may offer a more promising route towards individualized care.
At the level of neural circuitry, Maturana-Quijada et al.4 explore effective connectivity of the locus coeruleus in late-life MDD and amnestic mild cognitive impairment, providing a longitudinal perspective on mechanisms potentially linking affective and cognitive disorders in later life. Their findings, together with the accompanying commentary by Fauzi et al.,5 draw attention to the intersection between depression, cognition, and neurodegenerative processes and raise the clinically relevant question of whether trajectories of brain connectivity could eventually contribute to identifying patients with late-life depression at greater risk of cognitive decline. More broadly, they underscore the importance of moving from static, cross-sectional characterizations towards longitudinal models capable of capturing the dynamic trajectories of MDD.
Other contributions extend this dimensional perspective beyond diagnostic boundaries. Studies of the oxytocinergic system in borderline personality and eating disorders6 and of retinal thickness as a potential correlate of cognitive dysfunction in bipolar disorder7 illustrate how biologically relevant processes may cut across conventional psychiatric diagnoses. The latter is particularly illustrative of the growing search for accessible objective measures of clinically relevant dimensions, with retinal thinning showing associations with executive dysfunction. These findings remain preliminary and should not be interpreted as established clinical biomarkers, but they reinforce an important principle: precision psychiatry may ultimately depend less on finding biological signatures for individual diagnostic labels than on identifying mechanisms and markers associated with meaningful transdiagnostic dimensions such as cognition, emotional regulation, or interpersonal functioning.
Several articles in this issue also remind us that depression cannot be understood solely within the brain. Martín-Reina et al.8 report that patients with non-seasonal MDD experience lower overall and daytime light exposure and greater nighttime exposure than healthy controls, alongside poorer sleep quality. Although causality cannot be established, these findings highlight the close interplay between environmental light, sleep, circadian regulation, and depressive symptoms. Similarly, the commentary by Bariyyah et al.9 on the prospective study by Fortea et al.10 emphasizes evidence suggesting that simple coping behaviors – including physical exercise, spending time outdoors, and maintaining a balanced diet – may be associated with lower depressive and anxiety symptoms, whereas excessive exposure to distressing news may have the opposite effect. Such measures should not be viewed as substitutes for evidence-based treatments, but they broaden the therapeutic landscape towards modifiable aspects of daily life that may contribute to prevention, self-management, and recovery. Importantly, the authors call for further research to elucidate the specific mechanisms through which these behaviors may influence mental health and to identify additional coping strategies that could prove beneficial.
The relationship between mental and physical health is equally important. López-Cuadrado et al.,11 using data from more than 22,000 individuals in Spain linked to national mortality records over a median nine-year follow-up, show that depressive symptoms are associated with increased all-cause mortality after accounting for multiple sociodemographic, lifestyle, and health-related factors. Particularly noteworthy is the greater mortality observed among symptomatic individuals without a previous depression diagnosis and among those not receiving antidepressant treatment. Although the observational design precludes causal conclusions regarding the effects of diagnosis or treatment, these findings highlight the potential consequences of the depression treatment gap and remind us that the burden of depression extends beyond emotional distress and disability to physical health and survival. In parallel, the Spanish consensus by Pérez-Solà et al.12 on the detection and management of MDD with associated pain, and the subsequent commentary by Alcántara Montero,13 highlight the importance of systematically incorporating pain and other somatic symptoms into the assessment and treatment of depression. Beyond specific therapeutic recommendations, these contributions emphasize the need to overcome the traditional separation between mental and physical health care through integrated and collaborative models.
The wider environment also matters. Prates-Baldez et al.14 use the catastrophic 2024 floods in southern Brazil and Valencia to illustrate how climate-related disasters can simultaneously increase mental health needs and disrupt access to care. Their emphasis on early psychological support, social capital, and community resilience reminds us that vulnerability to depression is shaped not only by individual biology and behavior but also by the social and environmental contexts in which people live. Individual coping, community resources, and healthcare-system resilience should therefore be considered complementary rather than separate components of mental health prevention and care.
Finally, broadening our understanding of depression also requires reconsidering what we expect treatment to achieve. Peraire and Echeverria15 challenge the assumption that symptomatic remission must invariably remain the ultimate measure of successful psychiatric care. Building on the concept of difficult-to-treat depression, they introduce palliative psychiatry as a complementary framework for the relatively small group of patients experiencing persistent symptoms, functional impairment, and severe suffering despite multiple adequately delivered interventions. Importantly, this should not be understood as therapeutic abandonment. Rather, when complete recovery remains elusive, provided that we have considered and offered all appropriate and evidence-based treatment options, therapeutic priorities may need to encompass relief of suffering, harm reduction, subjective well-being, dignity, autonomy, and shared decision-making. Their perspective raises a difficult but necessary question: when remission cannot be achieved, how should we define meaningful therapeutic success?
Taken together, the contributions in this issue portray depression not as a homogeneous disorder captured by a symptom score, but as a complex and dynamic condition emerging from interactions among brain circuitry, stress biology, cognition, physical health, psychopathology, and the social and environmental context. This complexity should not encourage us simply to collect ever more biological or clinical data. Rather, it should prompt us to identify which dimensions matter for each patient and how they can inform prevention, treatment, and recovery. Moving beyond symptoms does not mean abandoning symptoms or the careful psychopathology on which psychiatry was built. It means understanding them more precisely and placing them alongside biological, cognitive, somatic, behavioral, environmental, and social information.
Ultimately, precision in depression should not be measured by the complexity of the data we collect, but by our ability to translate that complexity into better care and outcomes that matter to patients. Such outcomes extend beyond symptom reduction to include cognition, functioning, physical health, quality of life, autonomy, dignity, and relief from suffering. The challenge ahead is therefore not merely to understand depression in greater detail, but to use that understanding to provide the right care for the right patient, at the right stage of their illness.
Conflicts of interestNone declared.
